NDANASALGEL, METERED
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
NATESTO (testosterone) by Teva is androgen receptor agonists [moa]. First approved in 2014.
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATESTO is a nasal gel formulation of testosterone approved in 2014 for testosterone replacement therapy in hypogonadal men. It works as an androgen receptor agonist to restore physiological testosterone levels. The nasal delivery route offers an alternative to topical and injectable formulations with potentially faster absorption.
$0.587MPart D
Peak7.4 years to LOEProduct is in peak lifecycle stage with minimal Part D penetration (~$587K annually), suggesting a niche market position with limited team expansion opportunities.
Mechanism of Action
Androgen Receptor Agonists
Pharmacologic Class:
Androgen
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Started Oct 2027
300 enrolled
Spinal Cord InjurySpinal Cord InjuriesInjuries, Spinal Cord+11 more
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Started Jun 2026
0Multiple SclerosisErectile DysfunctionTestosterone Deficiency
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Started Mar 2026
60 enrolled
Metastatic Castration-resistant Prostate Cancer
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
Started Jul 2025
48 enrolled
Spinal Cord InjuriesEndothelial DysfunctionTestosterone Deficiency
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Started Mar 2025
100 enrolled
Hypogonadism, Male
Worked on NATESTO at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.